Myelodysplastic syndrome (MDS) is a diverse hematological malignancy with a wide spectrum of presentations and implications. Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international prognostic scoring system (IPSS-R). Bone marrow fibrosis (BMF) has been identified as an independent risk factor for poor survival in patients with MDS, irrespective of the IPSS-R risk category. However, BMF is not widely included in scoring systems and is not always considered by clinicians when making treatment decisions for patients. In this review, we discuss the available literature about the presentation and prognosis of patients with MDS and concurrent BMF. The prognostic impact of BMF should be factored in when deciding on transplant candidacy, especially for intermediate-risk patients.

中文翻译：

---

骨髓纤维化骨髓增生异常综合征：更新。

骨髓增生异常综合征 (MDS) 是一种多样化的血液恶性肿瘤，具有广泛的表现和影响。MDS 患者的治疗策略严重依赖预后评分系统，例如修订后的国际预后评分系统 (IPSS-R)。无论IPSS-R风险类别如何，骨髓纤维化（BMF）已被确定为MDS患者生存不良的独立风险因素。然而，BMF 并未广泛包含在评分系统中，临床医生在为患者做出治疗决策时并不总是考虑到这一点。在这篇综述中，我们讨论了有关 MDS 和并发 BMF 患者的表现和预后的现有文献。在决定移植候选资格时，应考虑 BMF 的预后影响，尤其是对于中危患者。